Taletrectinib Continues to Demonstrate High Clinical Activit

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Related Keywords

New York , United States , China , J Thor Onc , Christine Bestvina , Stephenv Liu , Alexander Drilon , Jason Porter , China National Medical Products Administration , Cancer Center , University Of Chicago Medicine Comprehensive Cancer Center , Georgetown University , National Medical Products Administration Of China , Research Institute , Lung Cancer Disease Research Group , Georgetown Lombardi Comprehensive Cancer Center , West Cancer Center , National Medical Products Administration , Thoracic Oncology , Developmental Therapeutics , Georgetown Lombardi Comprehensive Cancer , Early Drug Development Service , Memorial Sloan Kettering Cancer Center , Uchicago Medicine Comprehensive Cancer Center , Heart Therapeutics , Anheart Therapeutics , Ros1 Tki , Tyrosine Kinase Inhibitor , Os1 Positive Non Small Cell Lung Cancer , Nsclc , 2023 Esmo Congress , Phase 2 Trust Ii Trial , Taletrectinib ,